Vyvgart access in the UAE: the EDE named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Vyvgart (efgartigimod alfa-fcab) is the first-in-class neonatal Fc receptor (FcRn) antagonist approved for human use. It is FDA-approved for generalised myasthenia gravis (gMG) in adults regardless of antibody serostatus and, in the subcutaneous Vyvgart Hytrulo formulation, for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. In the United Arab Emirates, Vyvgart's regulatory status is uneven and the framework most patients use is the EDE named-patient corridor, with the specific clinical-justification angle anchored on the novel mechanism, the failure or intolerance of prior IVIG or plasma exchange, and the patient's MG-ADL or QMG functional scores. Reserved for you.

Why patients in the UAE need Vyvgart via NPP

Vyvgart sits at the intersection of two structural drivers. First, it represents an entirely new mechanistic category in autoimmune neurology. Patients with gMG who are intolerant of, or losing response to, chronic intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) often have no equivalent FcRn-antagonist option available through routine local stocking. The mechanistic difference matters clinically because FcRn antagonism produces a more targeted reduction in pathogenic IgG without the volume, infusion-reaction, or supply burden of repeat IVIG cycles. Second, country-level reimbursement and clinic-level stocking in MENA lag the regulatory landscape that has formed in the EU, UK, Japan, Canada, and China. Even where the molecule may be technically available via local agent pathways, clinic-level supply is not consistent and IV-suite scheduling for the 4-week cycle structure is not always integrated with routine neurology workflow.

Of the three structural access gaps documented in the UAE country module, Vyvgart falls primarily into the third pattern: not consistently registered or routinely stocked locally for the specific FcRn-antagonist mechanism. Where the locally available immunology stack is IVIG, PLEX, or complement inhibitors (eculizumab, ravulizumab), patients and neurologists requesting an FcRn antagonist specifically route through the EDE unregistered-medicine import permit. Reserve Meds verifies the current registration status at the time of each individual case rather than relying on a static published list.

The EDE named-patient pathway for Vyvgart

The federal pathway for a UAE-licensed physician to import a medicine not registered or not stocked locally is the unregistered-medicine import permit, administered through the EDE portal at ede.gov.ae since 29 December 2025. Vyvgart qualifies cleanly: it holds FDA approval (December 2021), EMA marketing authorisation (10 August 2022 for adult anti-AChR antibody positive gMG), MHRA approval, PMDA Japan approval, Health Canada approval, and NMPA China approval. The framework permits the import of a specific medicine for a specific patient when approved by a recognised reference authority and a clinically equivalent locally registered alternative is not suitable.

The Vyvgart clinical-justification angle in the EDE application is novel-mechanism-anchored. For a gMG patient, the letter documents the diagnosis with anti-AChR antibody serostatus (or seronegative status), MG-ADL (Myasthenia Gravis Activities of Daily Living) score, QMG (Quantitative Myasthenia Gravis) score where available, the disease trajectory, the prior-therapy stack (pyridostigmine, corticosteroids, azathioprine, mycophenolate, IVIG cycle history with response and tolerability documentation, PLEX history where applicable, complement inhibitor history where relevant), the rationale for FcRn antagonism as the next-line mechanism, the proposed dosing plan (10 mg/kg IV weekly for 4 weeks per cycle for the IV formulation, capped at 1,200 mg for patients 120 kg or more; or fixed-dose 1,008 mg subcutaneous Hytrulo weekly for 4 weeks), the planned cycle cadence (typically 4 to 5 cycles per year with next-cycle onset no sooner than 50 days from previous cycle start), and the monitoring plan including infection surveillance and pre-treatment vaccination status review. For a CIDP patient, the letter references the continuous weekly maintenance regimen rather than discrete cycles, anchored on the relapse-remitting disease pattern in CIDP and the June 2024 FDA approval for that indication.

A complete application includes the clinical justification letter signed by a UAE-licensed neurologist (MOHAP, DHA, DOH, or Sharjah Health Authority) practicing in the emirate of the dispensing facility, patient identifier, full product details (Vyvgart IV 400 mg per 20 mL single-dose vial or Vyvgart Hytrulo subcutaneous co-formulated with hyaluronidase, manufacturer argenx SE, planned cycle structure, total quantity), the destination dispensing facility license, and a chain-of-custody plan for the 2 to 8 degree Celsius cold-chain biologic. Approval timelines for routine first-cycle cases are typically 5 to 15 business days; novel-mechanism cases may extend toward the 4 to 6 week window for complex first imports.

Where Vyvgart gets dispensed in the UAE

Vyvgart IV requires hospital infusion-suite capability with cold-chain pharmacy storage and a neurology service line trained in the FcRn-antagonist cycle. The dispensing facility list narrows to institutions with neurology, complex autoimmune, and infusion-suite capability: Cleveland Clinic Abu Dhabi (M42 group, complex neurology), Sheikh Khalifa Medical City (SEHA network, managed by Cleveland Clinic), American Hospital Dubai (Mayo Clinic Care Network member, neurology), King's College Hospital London Dubai (UK-affiliated, neurology strength), Mediclinic City Hospital, and the neurology service lines at flagship NMC Healthcare sites. For Vyvgart Hytrulo subcutaneous, the same facilities apply, with the added option that after appropriate self-injection training the patient may complete subsequent weekly doses at home in coordination with the neurology team.

For patients outside the major centers, routing through a Dubai- or Abu Dhabi-based specialty importer holding a pharmaceutical establishment license is the standard practical path. The importer files the EDE permit, performs customs clearance for the refrigerated biologic, and delivers under chain-of-custody documentation with continuous temperature monitoring.

Real cost picture for Vyvgart in the UAE

US WAC for Vyvgart IV is reported in the range of approximately USD 63,000 to USD 95,000 per 4-week treatment cycle, with the variation driven by patient weight (which determines vial count). Annualised across the typical 4 to 5 cycles per year for gMG, this translates to approximately USD 300,000 to USD 450,000 per patient per year. Individual 20 mL IV vials are reported at approximately USD 6,000 to USD 6,200 in published price guides. Vyvgart Hytrulo pricing is set at parity to the IV product on a per-cycle basis. The AED is pegged to the US dollar at approximately 3.67 AED to 1 USD, so an annual gMG course at US WAC translates to approximately AED 1.1M to 1.65M before logistics and coordination overhead.

The all-in delivered-to-UAE cost typically includes US drug acquisition through argenx-authorised specialty distribution, validated cold-chain international logistics in the USD 600 to 2,500 (approximately AED 2,200 to 9,200) range per shipment depending on cycle size and destination emirate, nominal EDE permit and UAE customs fees, regulatory documentation handling, and the Reserve Meds coordination fee. Per-cycle procurement aligns with the 4-week cycle structure and the 50-day minimum inter-cycle interval. Reserve Meds quotes firm pricing only after weight-based dose calculation, dispensing facility, and shipping route are confirmed.

Insurance treatment varies. Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, and Orient assess novel-mechanism biologic imports case by case. Coverage for first-in-class agents tends to require detailed pre-authorisation, prior-line failure documentation, and disease-severity scoring. Cash-pay is the default posture at the order point; patient or hospital may pursue reimbursement after the fact.

Typical timeline for Vyvgart in the UAE

A cold-chain biologic case with a novel mechanism is at the deliberate end of the EDE timeline. Reserve Meds confirms eligibility within 24 to 48 hours and sends the documentation kit to the treating neurologist. EDE permit review for a first-cycle Vyvgart application typically runs 5 to 15 business days for routine cases and can extend to 4 to 6 weeks for complex first imports of a novel-mechanism biologic. US-side procurement, weight-based vial calculation, and cold-chain shipment add 5 to 10 business days once the permit is issued, plus a 2 to 3 day cold-chain customs and last-mile handoff to the hospital pharmacy. The full cycle for the first 4-week treatment cycle is typically 3 to 6 weeks from waitlist to first infusion. Subsequent cycles follow a more predictable cadence, with the 50-day minimum inter-cycle interval providing planning time for the next procurement.

What your physician needs to provide

The clinical justification letter, on the prescribing institution's letterhead and signed by a UAE-licensed neurologist practicing in the emirate of the dispensing facility, typically includes: gMG or CIDP diagnosis with antibody serostatus where applicable, MG-ADL and QMG scoring at intake (for gMG), disease duration and trajectory, prior-therapy history (pyridostigmine, corticosteroids, azathioprine, mycophenolate, IVIG with response and tolerability, PLEX, complement inhibitors where applicable), the rationale for FcRn antagonism as the next-line mechanism citing the ADAPT phase 3 trial (Howard et al., Lancet Neurology 2021), the proposed dosing plan with weight-based IV vial calculation or the Hytrulo subcutaneous regimen, the cycle structure and re-treatment plan, the monitoring plan including infection surveillance and vaccination status review before initiation, and the patient training plan for self-administration if Hytrulo is the planned formulation.

For Hytrulo cases, the letter documents the planned training for self-injection. For IV cases, the letter confirms the infusion-suite arrangement at the dispensing facility. The physician confirms their UAE license is in active standing at filing. The chain-of-custody plan for the cold-chain biologic is supplied by Reserve Meds for inclusion in the application.

Common questions about Vyvgart in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover Vyvgart?

Coverage for first-in-class FcRn antagonists is assessed case by case and typically requires detailed pre-authorisation with prior-line failure documentation. Some plans reimburse a percentage subject to copay; many require step therapy documentation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Will my DHA-licensed or DOH-licensed neurologist's letter be sufficient?

Yes. Any UAE-licensed neurologist practicing in good standing in the emirate of the dispensing facility has signing authority on the clinical justification letter. Joint-privilege neurologists who hold licenses across multiple emirates can file in any emirate where they are credentialed.

Can the subcutaneous Vyvgart Hytrulo formulation be self-administered at home?

Yes, after appropriate training. A prefilled-syringe presentation supports self-injection. The first cycle's training typically takes place at the dispensing facility or under neurology team supervision. The IV formulation remains an infusion-suite procedure.

What is the safety profile?

The ADAPT phase 3 trial in gMG reported a safety profile comparable to placebo across the treatment period. The most common adverse reactions in the FDA-approved labeling include upper respiratory tract infections, urinary tract infections, and headache. Infusion-related reactions and injection-site reactions are documented. Because FcRn antagonism reduces total circulating IgG, infection risk is a class consideration and warrants clinician monitoring.

How is the response to Vyvgart monitored?

Treating neurologists monitor for signs of infection during and between cycles, and assess clinical response using validated scales such as MG-ADL and QMG. IgG levels are reduced by approximately 60 to 70 percent at the nadir following a 4-week cycle, with recovery between cycles. Vaccination status is reviewed before starting therapy.

Are there other FcRn antagonists or alternatives?

Yes. Other approved FcRn antagonists have entered the gMG space, including rozanolixizumab (Rystiggo). Complement inhibitors such as eculizumab (Soliris) and ravulizumab (Ultomiris) are approved for anti-AChR antibody positive gMG and address a different node in the same pathway. IVIG and plasma exchange remain mainstays of acute and chronic management. The choice between these options is a neurologist-led discussion; Reserve Meds procures only against a prescriber-issued direction.

Where Reserve Meds fits in Vyvgart cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating neurologist, do not replace the EDE or any emirate-level authority, and do not replace the UAE dispensing pharmacy or infusion suite. What we do is orchestrate the US-side procurement of authentic argenx-supplied Vyvgart or Vyvgart Hytrulo, weight-based dose calculation, validated 2 to 8 degree Celsius cold-chain logistics with continuous temperature monitoring across the customs handoff, the regulatory documentation kit the treating neurologist needs, and a single named coordinator carrying the case through the full cycle structure. Vyvgart is a high-touch coordination case rather than a routine cross-border drug request. The Concierge Patient Coordinator carries the case across the cycle arc with the Cold Chain Quality Specialist signing off on every shipment release. No prior Reserve Meds case experience with Vyvgart specifically at the time of this page; standard NPP coordination plus cold-chain biologic protocols apply.

Next step

If the neurologist has recommended Vyvgart for gMG or CIDP and UAE access is the open question, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the neurologist's documentation kit.

Reserved for you.

---

This guide is informational, not medical or legal advice. The EDE named-patient framework requires a licensed UAE physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.